1-methyl-6-sulfanyl-5H-pyrazolo[3,4-d]pyrimidin-4-one | 5334-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-methyl-6-sulfanyl-5H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 4,5-dihydro-6-mercapto-1-methylpyrazolo[3,4-d]pyrimidin-4(1H)-one；4-Hydroxy-1-methylpyrazolo[3,4-d]pyrimidin-6-thiol；1-methyl-6-sulfanylidene-7H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS: 5334-27-0
• 化学式: C₆H₆N₄OS
• 分子量: 182.206
• InChiKey: GOABGLOSTBYANY-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 密度：
  1.78±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  91
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-6-sulfanyl-5H-pyrazolo[3,4-d]pyrimidin-4-one 在 三乙胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基苯胺 为溶剂， 反应 32.0h， 生成 (3S)-4-[6-(2-hydroxyethylamino)-1-methylpyrazolo[3,4-d]pyrimidin-4-yl]-N-(4-methoxy-2-methylphenyl)-3-methylpiperazine-1-carboxamide
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE PYRAZOLO-PYRIMIDINE THÉRAPEUTIQUEMENT ACTIFS

  摘要：

  一系列在4-位被一种二氮杂单环、桥接的双环或螺环基团取代的吡唑并[3,4-d]嘧啶衍生物，在治疗和/或预防各种人类疾病方面具有益处，包括炎症、自身免疫和肿瘤性疾病；病毒性疾病和疟疾；以及器官和细胞移植排斥。

  公开号：

  WO2014096423A1
• 作为产物：
  描述：

  硫脲 、 5-氨基-1-甲基吡唑-4-甲酰胺 生成 1-methyl-6-sulfanyl-5H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  Potential Purine Antagonists. XII. Synthesis of 1-Alkyl(aryl)-4,6-disubstituted Pyrazolo[3,4-d]pyrimidines¹

  摘要：

  DOI：

  10.1021/jo01100a025

文献信息

• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE BCDIN3D
  申请人：STORM THERAPEUTICS LTD

  公开号：WO2020254831A1

  公开（公告）日：2020-12-24

  The present invention relates to compounds that function as inhibitors and/or degraders of BCDIN3D activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCDIN3D activity is implicated.

  本发明涉及作为BCDIN3D活性抑制剂和/或降解剂的化合物。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病，如癌症，以及其他BCDIN3D活性有所涉及的疾病或病况中的应用。
• Heilmittelchemische Studien in der heterocyclischen Reihe. 25. Mitteilung. Pyrazolo-pyrimidine III Paraxanthin-, Theobromin- und Theophyllin-Analoga der Pyrazolo[3,4-d]pyrimidin-Reihe
  作者：P. Schmidt、K. Eichenberger、J. Dreuey

  DOI：10.1002/hlca.19590420132

  日期：——

  The preparation of the paraxanthine, theobromine and theophylline isomers 1,5-; 2,5- and 1,7-; 2,7- and 5,7-dimethyl-4,6-dioxo-4,5,6,7-tetrahydro-pyrazolo[3,4-d]-pyrimidines is described and their structure established. A structurally specific synthesis of the caffeine and isocaffeine isomers 1,5,7- and 2,5,7-trimethyl-4,6- dioxo-4,5,6,7-tetrahydro-pyrazolo [3,4-d]pyrimidines has been realized.

  对黄嘌呤，可可碱和茶碱异构体1，5-的制备；2.5和1.7；描述了2,7-和5,7-二甲基-4,6-二氧代-4,5,6,7-四氢-吡唑并[3,4-d]-嘧啶并确定了它们的结构。咖啡因和异咖啡因异构体1,5,7-和2,5,7-三甲基-4,6-二氧代-4,5,6,7-四氢吡唑并[3,4-d]嘧啶的结构特异性合成实现。
• Pyrazolothiazolopyrimidine derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05527908A1

  公开（公告）日：1996-06-18

  Pyrazolothiazolopyrimidine derivatives represented by the Formula ##STR1## and pharmaceutically acceptable salts thereof are useful as anti-inflammatory, analgesic, immunomodulatory and anti-ulcer agents.

  Pyrazolothiazolopyrimidine衍生物，由公式##STR1##代表，以及其药用可接受的盐，可用作抗炎、镇痛、免疫调节和抗溃疡剂。
• Therapeutically Active Pyrazolo-Pyrimidine Derivatives
  申请人：UCB PHARMA S.A.

  公开号：US20160194329A1

  公开（公告）日：2016-07-07

  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

  一系列在4位点取代了含有一环氮杂原子的单环、桥环或螺环的嘧唑并[3,4-d]嘧啶衍生物，在治疗和/或预防各种人类疾病方面具有益处，包括炎症、自身免疫和肿瘤性疾病；病毒性疾病和疟疾；以及器官和细胞移植排斥反应。
• Pyrazolothiazolopyrimidine derivatives as a novel class of anti-inflammatory or antinociceptive agents: synthesis, structural characterization and pharmacological evaluation
  作者：F Russo、S Guccione、G Romeo、G Uccello Barretta、S Pucci、A Caruso、M Amico-Roxas、V Cutuli

  DOI：10.1016/0223-5234(93)90123-v

  日期：1993.1

  As a part of a research program on anti-inflammatory-analgesic compounds, pyrazolothiazolopyrimidines 5a-f and 5g-i were prepared by cyclodehydration in 98% H2SO4 or PPA of the corresponding 6-thioketomethylene-substituted-4-hydroxy-pyrazolo[3,4-d]pyrimidines 2a-i and 2g-i. The results of the pharmacological in vivo screening indicate an interesting dissociation of the analgesic from the anti-inflammatory activity depending on aromatic or aliphatic substitution at the C4 of the thiazole ring. Analgesic activity was not associated with any narcotic effect; in addition, all the active compounds showed a remarkable systemic and gastric tolerance. This indicated a mode of action different from that of the classical nonsteroidal anti-inflammatory drugs, acting on prostaglandin biosynthesis. To clarify the mechanism or the mechanisms underlying the pharmacological activity of these and other closely related compounds, we initiated a 'file chemical approach' to various systems involved in the inflammatory process. At present, some of the more active in vivo compounds tested as substance P antagonists showed a moderate and possibly non-specific effect on NK1 and NK2 receptors.